News – Page 264 – Endpoints News

SUBSCRIBE

Gilead needs a big R&D hit. Here's why claims on NASH fall well short of that

4 years ago

Investors add $17M to Emulate Series B as Covance partners; UMass professor to work with Spark on next-gen vectors

4 years ago

Backed by neuro enthusiast Arch, upstart BlackThorn tackles some tough targets with $40M round

4 years ago

Rigel’s 2nd PhIII for fostamatinib scuttled by a single placebo response, shares crater

4 years ago

No surprise: AbbVie turns cold shoulder to a messy rheumatoid arthritis partnership with Ablynx

4 years ago

Eli Lilly wins a quick OK for new sarcoma drug olaratumab

4 years ago

Now that Sarepta has bolted out of the barn, the FDA wants to shut the door

4 years ago

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug

4 years ago

Novartis throws Cerulean a lifeline with $5M deal; Porges disses Celgene’s GED-0301

4 years ago

Cancer powerhouse Roche elbows its way into a checkpoint showdown with Bristol-Myers, Merck

4 years ago

Oxford spinout Argonaut looks to hack cancer cells and program them to die

4 years ago

Merck bags a PhIII CMV victory in the wake of a flop at rival Chimerix

4 years ago

Gene editing loses its sizzle. CRISPR Therapeutics IPO debuts beneath the range

4 years ago

Kite CEO Arie Belldegrun preps for a looming date with the FDA as he tackles first-mover advantage in CAR-T

4 years ago

New Vancouver-based fund has $100M to invest in biotech; FDA hands out $23M in rare disease R&D grants

4 years ago

The Medicines Company touts fresh evidence that their PCSK9si can durably bat down LDL

4 years ago

Nancy Stagliano bags another $45M for True North’s rare disease R&D

4 years ago

Armed antibody player ADC lands a $105M mega-round to back pipeline construction

4 years ago

Pfizer launching first US mAb biosimilar with Remicade knockoff, but you can forget about any fire sale

4 years ago

Vertex snares $75M windfall in revised CFF deal; Ex-Celgene R&D prez Daniel starts advisory group

4 years ago

Sofinnova bags $650M for a dedicated biotech fund

4 years ago

PTC shares plunge anew after FDA slaps down Duchenne drug for a second time

4 years ago

Safety threat forces FDA to put a hold on Regeneron, Teva’s big NGF pain drug fasinumab

4 years ago

Clinton campaign staff: "We have started the war with pharma!!"

4 years ago

First page Previous page 261 262 263264265 266 267 Next page Last page